Physician profile
Jeffrey B Cates
NPI 1760543714
$11,110.78
in general payments reported to CMS, 2019-2025
16 companies · $2,499 in 2025
The $2,499 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,622 · 2020: $396 · 2021: $688 · 2022: $435 · 2023: $2,021 · 2024: $2,451 · 2025: $2,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,968 · Education: $2.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,968.11 |
| Education | $2.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $4,280.82 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $1,501.81 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,392.57 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Indivior INC. | $847.58 | 2019-2025 | Perseris, Sublocade |
| Axsome Therapeutics, INC. | $554.52 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $388.79 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $379.49 | 2019-2020 | |
| Abbvie INC. | $369.10 | 2022-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $332.53 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $323.60 | 2024-2025 | Uzedy, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $270.91 | 2019 | |
| Lundbeck LLC | $195.47 | 2020-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $102.18 | 2019-2025 | Fanapt |
| Braeburn INC. | $84.46 | 2025 | Brixadi |
| Noven Therapeutics, LLC | $53.15 | 2023 | Xelstrym, Secuado |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $33.80 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Cates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.